PMCPA Case
| Case number | AUTH/2431/8/11 |
| Complainant | General practitioner |
| Company | Eli Lilly and Company Limited |
| Product | Bydureon (exenatide) |
| Material | Advertisement/outsert attached to July/August 2011 edition of Practical Diabetes |
| Issue | Legibility of prescribing information (contrast and readability) |
| Clause(s) considered | Clause 4.1 |
| Panel finding | No breach |
| Notable Panel comments | Grey text on white background “not helpful”; on the limits of acceptability for contrast; ‘max’ subscript not legible in places but understandable in context |
| Complaint received | 10 August 2011 |
| Case completed | 7 September 2011 |
| Appeal | No appeal |
| Additional sanctions | None stated |
Download the full case report (PDF)
Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory
Got a question about this case?
Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.
⭐ Business Intelligence Access
See the full compliance picture for every pharma company
291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export.
One real case. One key lesson. Every week — free.